Browsing by Author Lee, Chee Khoon

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 18 of 18
Issue DateTitleAuthor(s)Citation
2014Can we accurately report PTEN status in advanced colorectal cancer?Lee, Chee Khoon; Broadbridge, Vy; Cooper, John; Hardingham, Jennifer; Hocking, Christopher; Price, Timothy; Ruszkiewicz, Andrew; Tebbutt, Niall; Townsend, Amanda; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials CentreCan we accurately report PTEN status in advanced colorectal cancer?, BMC Cancer, vol.14, 1, 2014,pp 1-7
2017Checkpoint Inhibitors in Metastatic EGFR-Mutated Non`Small Cell Lung Cancer A Meta-AnalysisGebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Links, Matthew; Man, J; Mok, Tony; Yang, J; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCheckpoint Inhibitors in Metastatic EGFR-Mutated Non`Small Cell Lung Cancer A Meta-Analysis, Journal of Thoracic Oncology, vol.12, 2, 2017,pp 403-407
2017Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trialAsher, Rebecca; Beale, Philip; Kwok, John; Lee, Chee Khoon; Park, Susanna; Friedlander, Michael; Selle, Frederic; NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; Central Clinical School: Medicine; NH&MRC Clinical Trials Centre; School of Medical Sciences: PhysiologyClinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial, Annals of Oncology, vol.28, 11, 2017,pp 2733-2740
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerGebski, Val; Lee, Chee Khoon; Mann, Kristy; Simes, Robert John; Wilson, Kate; Bruhn, M; Cunningham, David; Hardingham, Jennifer; Price, Timothy; Robinson, B; Tebbutt, Niall; Townsend, Amanda; van Hazel, Guy; Weickhardt, Andrew; Wrin, Joseph; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCorrelation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer, British Journal of Cancer, vol.112, 6, 2015,pp 963-970
2015Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinibGibbs, Emma; Lee, Chee Khoon; Lord, Sarah (Sally); Casali, Paolo G.; Cioffi, Angela; et al, Various; Goldstein, David; Joensuu, Heikki; Maki, Robert; Verweij, Jaap; Zalcberg, John; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreDevelopment and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib, European Journal of Cancer, vol.51, 7, 2015,pp 852-860
2017Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survivalDavies, Lucy; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Marschner, Ian; Fukuoka, Masahiro; Gralla, Richard J; Inoue, Akira; Mitsudomi, Tetsuya; Mok, Tony; Nakagawa, Kazuhiko; Rosell, Rafael Costa; Thongprasert, Sumitra; Tu, Yu-Kang; Wu, Yi-long; Yang, James; Zhou, Caicun; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreGefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival, Journal of the National Cancer Institute, vol.109, 6, 2017,pp 1-13
2015Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trialGebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Ferrero, A.; Friedlander, Michael; Grunewald, Tami; Hardy-Bessard, Anne Claire; Harter, Philipp; Heywood, M; Pujade-Lauraine, Eric; Scambia, G; Schauer, C; Sehouli, Jalid; Vergote, Ignace; Woie, Kathrine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreImpact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial, Gynecologic Oncology, vol.136, 1, 2015,pp 18-24
2015Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisDing, Pei Ni; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Pavlakis, Nick; Gralla, Richard J; Inoue, Akira; Links, Matthew; Mitsudomi, Tetsuya; Rosell, Rafael Costa; Wu, Yi-long; Yang, James Chic-Hsin; Zhou, Ci-Xiang; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: MedicineImpact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, Journal of Clinical Oncology, vol.33, 17, 2015,pp 1958-1965
2014Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosisHoussami, Nehmat; Lee, Chee Khoon; Lord, Sarah (Sally); Tjokrowidjaja, Angelina; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreMetastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis, Internal Medicine Journal, vol.44, 8, 2014,pp 764-770
2017Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung CancerLee, Chee Khoon; Ahn, Myung-Ju; Akamatsu, Hiroaki; et al, Various; Garassino, Marina; He, Yong; Kim, Hye; Mok, T. S. K.; Ramalingam, Suresh; Shepherd, Frances; Wu, Yi-long; NH&MRC Clinical Trials CentreOsimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, New England Journal of Medicine, vol.376, 7, 2017,pp 629-640
2014Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian CancerKing, Madeleine; Lee, Chee Khoon; Stockler, Martin; Arranz, José Angel; de Gregorio, Nikolaus; et al, Various; Friedlander, Michael; Hilpert, Felix; Joly, Florence; Mirza, Mansoor Raza; Wenzel, Lari; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePatient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer, Journal of Clinical Oncology, vol.32, 13, 2014,pp 1309-1319
2014Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancerLee, Chee Khoon; Arentz, Georgia; Bruhn, Maressa; Cunningham, David; Hardingham, Jennifer; Hocking, Christopher; Price, Timothy; Shivasami, Aravind; Tebbutt, Niall C; Townsend, Amanda; Wrin, Joseph; School of Public Health: NH&MRC Clinical Trials CentreProangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer, International Journal of Cancer, vol.135, 3, 2014,pp 731-741
2017Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudyAsher, Rebecca; Davies, Lucy; Gebski, Val; Gibbs, Emma; King, Madeleine; Lee, Chee Khoon; Roncolato, Felicia; Stockler, Martin; Friedlander, Michael; Hilpert, Felix; Pujade-Lauraine, Eric; Wenzel, Lari; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Psychology; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreQuality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy, Annals of Oncology, vol.28, 8, 2017,pp 1849-1855
2017Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trialGebski, Val; Gibbs, Emma; Lee, Chee Khoon; Coeffic, D; et al, Various; Garcia, Yolanda; Hilbert, Felix; Huizing, M; Kaern, Janne; Roemer-Becuwe, C; Sorio, R; Witteveen, P; Zagouri, F; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreSafety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial, Gynecologic Oncology, vol.144, 1, 2017,pp 65-71
2016Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancerDavies, Lucy; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Marschner, Ian; Simes, Robert John; Cameron, David; de Souza, Paul; Di Leo, Angelo; Ellis, Catherine; Geyer, Charles; Johnston, Stephen; Loi, Sherene; Press, Michael F.; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreSerum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer, Journal of Clinical Oncology, vol.34, 9, 2016,pp 936-944
2016Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3Lee, Chee Khoon; Au, Heather Jane; Brundage, M.D.; Goldstein, David; Jonker, Derek J.; Moore, Malcolm J.; O'Callaghan, Chris J.; Parulekar, Wendy R.; Ringash, Jolie; Tu, Dongsheng; Vickers, Michael M.; Wheatley-Price, Paul; NH&MRC Clinical Trials CentreSignificance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3, Pancreatology, vol.16, 6, 2016,pp 1106-1112
2013Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneCoates, Alan; Gebski, Val; Lee, Chee Khoon; Simes, Robert John; Tattersall, Martin; Veillard, Anne-Sophie; Brigham, Brian; Byrne, Michael J.; Forbes, John; Harvey, V; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreTrade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone, SpringerPlus, vol.2, 391, 2013,pp 1-10
2015Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancerByth Wilson, Karen; Cummins, Michelle; Lee, Chee Khoon; Simes, Robert John; Asadi, K; Chionh, F; Mariadason, John M; Murone, C; Nagtegaal, ID; Price, Timothy; Punt, Cornelis JA; Scott, Andrew M; Tebbutt, Niall; Weickhardt, Andrew J; Williams, DS; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreVascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer, British Journal of Cancer, vol.113, 1, 2015,pp 37-45